Seeking Novel Therapeutics for Anxiety Management

Background

A global health company is seeking novel therapeutics for chronic and situational anxiety management. They are interested in rapid-onset treatments that can be administered daily (4-6 hours efficacy) for situational anxiety or as a long-acting monthly treatment for chronic anxiety, with minimal side effects.

Approaches of interest:

• Novel therapeutic approaches, preferably with validation in canine models
• Non-invasive delivery methods (oral, topical, or injectable for long-acting)
• Serotonergics, 5-HT1A partial agonists, GABAergics, HPA axis mechanisms
• Small molecules, peptides, monoclonal antibodies, and biopharma assets

Out of scope:

• Approaches using hallucinogens/psychedelics or natural products
• SSRIs and SRNIs (unless rapid onset can be achieved)

Developmental stage of interest:

Opportunities should have in vivo validation of safety and efficacy, preferably with canine data. Human-validated opportunities with potential for repurposing are also considered.

Email Cameron Sargent, CTTC Licensing Officer for Biotechnology and Health Science Licensing, at Cameron.Sargent@Vanderbilt.edu for more information.